Roche. YTD September 2017 sales. Basel, 19 October 2017

Transcription

1

2 Roche YTD September 2017 sales Basel, 19 October 2017

3 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected. 3

4 Group Severin Schwan Chief Executive Officer 4

5 YTD Sept 2017 performance Outlook 5

6 YTD Sept 2017: Strong sales growth in both divisions Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division Diagnostics Division Roche Group CER=Constant Exchange Rates 6

7 YTD Sept 2017: Strong sales growth in US and International CHFbn % -1% % -1% +14% +1% +10% +2% +1% +4% -2% +2% Japan International Europe US Diagnostics Pharma All growth rates at Constant Exchange Rates (CER) 7

8 Q3 2017: Sales growth for the sixth consecutive year 10% 8% 8% 7% 7% 6% 6% 6% 6% 5% 5% 6% 6% 6% 6% 6% 4% 2% 2% 4% 4% 4% 5% 4% 4% 3% 3% 4% 0% Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 All growth rates at Constant Exchange Rates (CER) 8

9 YTD Sep 2017: Successful launch activities Differentiation driving growth Additional sales of recent launches CHF Alecensa +122m Tecentriq +278m EU: Positive CHMP opinion in 1L ALK+ NSCLC US: 1L under FDA priority review and listing in NCCN guidelines as category 1 preferred option EU approval in bladder (1/2L) & lung (2L) Ocrevus +500m Approved in RMS & PPMS: US, CH, Australia Positive early feedback from all stakeholders Total: +900m PPMS=primary progressive multiple sclerosis; RMS=relapsing forms of multiple sclerosis; NCCN=National Comprehensive Cancer Network; CHMP=Committee for Medicinal Products for Human Use 9

10 Q3 2017: Sustainable Roche business case Important milestones achieved HER2 franchise Perjeta in adjuvant BC (APHINITY) US priority review, EU filed CD20/Hematology Gazyva in 1L inhl (GALLIUM) Venclexta in R/R CLL (MURANO) Polatuzumab in R/R DLBCL (Ph II) US priority review, EU approved Ph 3 met primary endpoint BTD, EU PRIME designation Cancer Immunotherapy Tecentriq EU approved in bladder and lung Lung cancer Alecensa in 1L ALK+ NSCLC US priority review, positive CHMP opinion Hemophilia A Emicizumab in inhibitors (HAVEN 1 and 2) BTD, US priority review, EU accelerated assessment Neuroscience Ocrevus Additional approvals in AUS, CAN, CH Spinal Muscular Atrophy SMN2 splicer (SUNFISH) Ph 1b at WMS* Pivotal Ph III initiated * WMS=World Muscle Society, October 2017; BTD=breakthrough therapy designation 10

11 Roche significantly advancing patient care Recognition for innovation 2013-present 18 Breakthrough Therapy Designations Rank Company # 1 Roche 18 2 Novartis 15 3 BMS 10 4 Merck 9 4 Pfizer 9 Source: as of October 2017; BR=bendamustin+Rituxan; DLBCL=diffuse large B cell lymphoma; LDAC=low dose cytarabine; AML=acute myeloid leukemia; ECD=Erdheim-Chester disease; NSCLC=non-small cell lung cancer; PPMS=primary progressive multiple sclerosis; HMA=hypomethylating agent; CLL=chronic lymphocytic leukemia; IPF=idiopathic pulmonary fibrosis 11

12 YTD Sept 2017 performance Outlook 12

13 Aiming to set new standards of care Upcoming readouts for CIT & Hematology Readouts: (Q4 17 to Q2 18) Lung Most comprehensive lung cancer program addressing all common backbones 5 trials in non-squamous, squamous & small cell lung cancer GU Among the leaders in renal cancer 1L RCC Breast First-in-class in triple negative breast cancer 1L TNBC CRC First-in-class in colorectal cancer 2/3L CRC Hemophilia First-in-class in non-inhibitor hemophilia A Non-inhibitors and monthly schedule 13

14 Launch of new medicines at a record high Emicizumab (filed)

15 2017 outlook raised at HY Group sales growth 1 Mid-single digit Core EPS growth 1 Broadly in line with sales growth Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 15

16 Pharmaceuticals Division Daniel O Day CEO Roche Pharmaceuticals 16

17 YTD Sept 2017 sales Innovation Outlook 17

18 YTD Sept 2017: Pharma sales Strong growth in US due to ongoing launches Change in % CHFm CHFm CHF CER Pharmaceuticals Division 30,636 29, United States 15,266 13, Europe 6,766 6, Japan 2,675 2, International 5,929 5, CER=Constant Exchange Rates 18

19 YTD Sept 2017: Strong sales performance with increasing contribution from new launches Ocrevus Tecentriq Perjeta Xolair Actemra/RoActemra MabThera/Rituxan Alecensa Herceptin Activase/TNKase Esbriet Lucentis Pegasys Tamiflu Avastin Tarceva CHFm -21% -2% -17% -36% +11% +4% +17% +13% +102% +2% +14% +17% +2% +357% US Europe Japan International n/a Absolute values and growth rates at Constant Exchange Rates (CER) 19

20 YTD Sept 2017: Oncology with +3% growth YoY CER growth HER2 Avastin CD20 Herceptin MabThera/Rituxan (Oncology) Perjeta -2% Gazyva/Gazyvaro +3% Kadcyla +6% Perjeta: Strong growth in all regions Kadcyla: Growth driven by International, US, and EU Breast cancer reimbursement in France, CIT competition in US US: Gazyva in 1L FL (GALLIUM) on NCCN guidelines EU: Approval in 1L FL achieved Tarceva Tecentriq Alecensa Cotellic + Zelboraf CHFbn -17% +357% +102% Cotellic -12% Increased competition EU: Approval in lung (2/3L) and bladder (2L and 1L cisplatin ineligible) achieved US: NCCN category 1 listing in 1L as preferred option US/EU: 1L filing completed (Positive CHMP opinion) US: Cotellic+Zelboraf stable 1/2L market share EU: Cotellic+Zelboraf increasing; Zelboraf mono declining YTD Sept 2017 Oncology sales: CHF 19.2bn; All growth rates at Constant Exchange Rates (CER); CIT=cancer immunotherapy; FL=follicular lymphoma; NCCN=National Comprehensive Cancer Network 20

21 HER2 franchise: Growth driven by Perjeta and Kadcyla CHFm 2,500 2, % +16% +8% YoY CER growth +5% HER2 franchise Q Perjeta (+17%): Strong demand in neoadj. and 1L BC driven by all regions 1,500 Kadcyla (+10%): Growth in International, US and EU 1,000 Outlook 2017 US: Priority review for APHINITY (adj. BC) with PDUFA date set for Jan EU filing of APHINITY completed 0 Q3 14 Q3 15 Q3 16 Q3 17 Herceptin Perjeta Kadcyla CER=Constant Exchange Rates; BC=breast cancer; SC=subcutaneous 21

22 Immunology: Differentiation and new indications contributing to strong growth CHFm 2,000 1,600 1, % +23% +10% YoY CER growth +8% Immunology Q Xolair (+17%) Asthma: US pediatrics launch ongoing; only biologic approved for children Actemra (+13%) 800 EU approval in giant cell arteritis Q3 14 Q3 15 Q3 16 Q3 17 MabThera/Rituxan (RA) Actemra SC CellCept Esbriet Actemra IV Xolair Pulmozyme Other US approval for CRS MabThera/Rituxan (+6%) Continues to grow in rheumatoid arthritis and vasculitis (GPA and MPA) CER=Constant Exchange Rates; CRS=cytokine release syndrom; GPA=granulomatosis with polyangiitis; MPA=microscopic polyangiitis 22

23 Ophthalmology: Lucentis stabilized due to prefilled syringe and new indications Lucentis Q US (+8%): Growth driven by prefilled syringe and new indications DR and mcnv Outlook 2017/18 Overall FY growth expected Ph II enrolment into port delivery study completed; results expected in 2018 Ph II results for anti-vegf/ang2 bispecific antibody with dual MoA expected in 2018 DR=diabetic retinopathy; mcnv=myopic choroidal neovascularisation; wamd=wet age-related macular degeneration; DME=diabetic macular edema; MoA=mechanism of action 23

24 Neuroscience: Ocrevus with excellent launch in all treatment lines in RMS and PPMS CHFm Ocrevus Q Continued strong uptake in RMS and PPMS (60/40) with some bolus in PPMS Market research indicates inroads in all treatment lines in RMS RMS: 30% treatment naive/previously discontinued vs. 70% switches from all other approved medications Broad base of prescribers and high level of US insurance coverage 0 Q1 17 Q2 17 Q3 17 US Europe International Outlook 2017 EU launch preparations on track RMS=relapsing forms of multiple sclerosis; PPMS=primary progressive multiple sclerosis 24

25 YTD Sept 2017 sales Innovation Outlook 25

26 Recognition for innovation 2013-present Two additional BTDs in hematology received 18 Breakthrough Therapy Designations Rank Company # 1 Roche 18 2 Novartis 15 3 BMS 10 4 Merck 9 4 Pfizer 9 = BTDs in blood cancer Source: as of October 2017; BR=bendamustin+Rituxan; DLBCL=diffuse large B cell lymphoma; LDAC=low dose cytarabine; AML=acute myeloid leukemia; ECD=Erdheim-Chester disease; NSCLC=non-small cell lung cancer; PPMS=primary progressive multiple sclerosis; HMA=hypomethylating agent; CLL=chronic lymphocytic leukemia; IPF=idiopathic pulmonary fibrosis 26

27 Late-stage hematology: Improving the standard of care and extending into new indications Incidence rates (330,000 pts 1 ) Ph III 1L (CLL14) Ph III R/R (MURANO) + Ph III Ph II R/R Ph III 1L (POLARIX) + Polatuzumab vedotin Ph III Idasanutlin Ph III ¹ Datamonitor; incidence rates includes the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); CLL=chronic lymphoid leukemia; DLBCL (anhl)=diffuse large B-cell lymphoma; inhl=indolent non-hodgkin`s lymphoma; AML=acute myeloid leukemia; MM=multiple myeloma; MDS=myelodysplastic syndrome; ALL=acute lymphoblastic leukemia; Venclexta in collaboration with AbbVie; Gazyva in collaboration with Biogen; Polatuzumab vedotin in collaboration with Seattle Genetics 27

28 Hematology pipeline progress in molecules in combination testing 2x 2x = progress in 2017 * Venclexta in collaboration with AbbVie; Polatuzumab vedotin in collaboration with Seattle Genetics; Cotellic in collaboration with Exelixis; ChK1i in collaboration with Array BioPharma; NHL=non-hodgkin`s lymphoma; CLL=chronic lymphoid leukemia; MM=multiple myeloma; MDS=myelodysplastic syndrom; AML=acute myeloid leukemia 28

29 APHINITY: Perjeta+Herceptin in HER2+ ebc Priority review by the FDA Risk of recurrence or death reduced by 19% in all patients, 23% in node+ and 24% in HR- patients von Minckwitz et al, ASCO 2017; ebc=early breast cancer (adjuvant setting); HR=hormone receptor; * Target population for Herceptin in adjuvant breast cancer (US & EU5); current Herceptin penetration ~95%; Source: Datamonitor and internal estimates 29

30 Emicizumab s clinical development plan HAVEN 3 results expected in Q Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Noninterventional 221 patients HAVEN1 inhibitor adults/adolescents ( 12 years old), qw 113 patients inhibitor children (0 11 years old), qw HAVEN2 62 patients HAVEN3 non-inhibitor adults/adolescents ( 12 years old), qw and q2w 152 patients Q4 HAVEN4 non-inhibitor/inhibitor adults/adolescents, q4w 48 patients H

31 YTD Sept 2017 sales Innovation Outlook 31

32 Aiming to set new standards of care Upcoming readouts for CIT & Hematology Readouts: (Q4 17 to Q2 18) Lung Most comprehensive lung cancer program addressing all common backbones 5 trials in non-squamous, squamous & small cell lung cancer GU Among the leaders in renal cancer 1L RCC Breast First-in-class in triple negative breast cancer 1L TNBC CRC First-in-class in colorectal cancer 2/3L CRC Hemophilia First-in-class in non-inhibitor hemophilia A Non-inhibitors and monthly schedule 32

33 2017: Key late-stage news flow Compound Indication Milestone Alecensa 2L ALK+ NSCLC EU approval Ocrevus RMS / PPMS US/EU launch Tecentriq 1L cisplatin ineligible mubc US approval Regulatory Tecentriq 2/3L NSCLC and 1/2L mubc EU approval Gazyva 1L FL (inhl) US/EU filing Actemra Giant cell arteritis US/EU approval emicizumab Hemophilia A inhibitors US/EU filing Perjeta + Herceptin Adjuvant HER2+ BC Ph III APHINITY Alecensa 1L ALK+ NSCLC Ph III ALEX Phase III readouts* Venclexta + Rituxan R/R CLL Ph III MURANO Tecentriq + chemo/ Tecentriq + chemo + Avastin 1L NSCLC Ph III IMpower150 lampalizumab Geographic atrophy Ph III SPECTRI/CHROMA emicizumab Hemophilia A non-inhibitors Ph III HAVEN3 Additional YTD news flow: Lucentis: Approval in mcnv and diabetic retinopathy Rituxan Hycela for blood cancers approved and launched in the US Emicizumab: Positive interim results in pediatric inhibitors (HAVEN2) Gazyva 1L FL: EU approval achieved; FDA priority review (PDUFA date Dec 23) Alecensa 1L ALK+ NSCLC: Positive CHMP opinion and FDA priority review (PDUFA date Nov 30) Outcome studies are event-driven: timelines may change; mcnv=choroidal neovascularisation secondary to myopia 33

34 Diagnostics Division Roland Diggelmann CEO Roche Diagnostics 34

35 YTD Sept 2017: Diagnostics Division sales Growth driven by CPS & Tissue Diagnostics Change in % CHFm CHFm CHF CER Diagnostics Division 8,798 8, Centralised and Point of Care Solutions 5,211 4, Diabetes Care 1,464 1, Molecular Diagnostics 1,388 1, Tissue Diagnostics CER=Constant Exchange Rates Underlying growth of Molecular Diagnostics excluding sequencing business: +4% 35

36 YTD Sept 2017: Diagnostics regional sales Growth in all regions North America +1% 25% of divisional sales EMEA 1 +3% 40% of divisional sales Japan +1% 4% of divisional sales Latin America +11% 7% of divisional sales Asia Pacific +15% 24% of divisional sales +18% growth in E7 countries 2 1 Europe, Middle East and Africa; 2 Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at Constant Exchange Rates 36

37 YTD Sept 2017: Diagnostics Division highlights Growth driven by Immunodiagnostics YoY CER growth Centralised and Point of Care Solutions +7% Driven by immunodiagnostics (+13%); clinical chemistry (+3%) Diabetes Care -2% Continued US pricing and reimbursement pressures Molecular Diagnostics 1 +3% Virology (-2%); Blood screening (+4%) Tissue Diagnostics +13% EMEA North America RoW Advanced staining portfolio (+10%); primary staining (+13%) and companion diagnostics (+32%) CHFbn Underlying growth of Molecular Diagnostics excluding sequencing business: +4% CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa 37

38 Implementing the fully integrated core laboratory Connecting disciplines (cobas 6800/8800, cobas 6500, cobas p 612) Highest throughput analysers (cobas e 801, cobas c 702) Comprehensive menu (Procalcitonin; Zika; MPX; Syphilis) Digitalised data management (Navify tumor board) Seamless workflow and laboratory IT (cobas connection modules) 38

39 Continued momentum of cobas e 801 placements Completion of serology blood screening panel Blood screening assays HIV Duo* Anti-HCV II HBsAg II Anti-HBc II Anti-HBs II HTLV-I/II Syphilis CMV lgg CMV IgM Chagas cobas e 801 Double throughput on same footprint 517 instruments placed in 28 markets * Launched in 2017 Note: Serology assays are CE marked according to Directive 98/79/EC. Test performance has been established according to the Common Technical Specifications (CTS) for diagnostic use and for screening of blood donations *only on cobas e 801, HIV combi PT is continued on cobas e 602, e 601 and e

40 Targeting medication to atrial fibrillation patients GDF-15 test predicts individual bleeding-risk 33 million people with atrial fibrillation globally, at increased risk of stroke Today 50% of patients receive no stroke prevention treatment due to perceived bleeding risk GDF-15 informs on individual bleeding risks and allows for more targeted treatment decisions Figure 3: Importance of variables considered for inclusion in the ABC-bleeding score (ARISTOTLE derivation cohort; n=14,537) as assessed by Wald Regression. Adapted from Hijazi The improved prognostic value of the ABC bleeding risk score is recognized in the 2016 European Society of Cardiology Guidelines for the management of atrial fibrillation 40

41 FDA approval of first commercial Zika IVD test Expanding our leading blood screening portfolio Zika outbreak confirmed in Brazil WHO declares international Public Health Emergency Screening of Puerto Rico donations with cobas Zika IND* FDA mandates US screening for Zika virus FDA approval of cobas Zika test MAY 2015 DEC 2015 FEB 2016 MAR 2016 APR 2016 JUL 2016 AUG 2016 APR 2017 OCT 2017 Locally-acquired Zika cases reported in Puerto Rico cobas Zika test receives IND* status from FDA Transmission of Zika virus reported in Miami, FL BLA** submission to FDA for cobas Zika cobas 6800/8800 Systems: 313 instruments placed in 33 markets*** *IND: Investigational New Device **BLA: Biologics License Application ***Status YTD August

42 Launch of NAVIFY tumor board Entering digital information systems market Oncology care team workflow and decision support tool Aggregates patient data from multiple sources into a dashboard Improved team collaboration and efficiency, reduces errors Auditable decision tracking Patient data stored and accessed securely 42

43 Key launch list 2017 Instruments/ Devices Tests/ Assays Area Product Market Central Laboratory Coagulation Testing Point of Care Diabetes Care HPV Virology Sequencing cobas Liat cobas 8000 <e 801> High throughput immunochemistry analyser CCM High Speed cobas connection module (CCM) for up to 6000 samples/hour cobas t 511 / t 711 Medium and high volume coagulation systems CoaguChek Vantus Hand-held coagulation monitoring system for Patient Self- Testing Accu-Chek Instant bg System Effortless, accurate and affordable bg system for price sensitive markets cobas HPV Next generation HPV DNA test leveraging 68/8800 Automation to detect 14 hrhpv with simultaneous detection of genotypes 16 and 18 CINtec Histology Diagnostic component of the Roche Cervical Cancer portfolio cobas HIV 1&2 Qual For use on the cobas 6800/8800 Systems; for diagnosis of acute HIV 1 or 2 infection and for confirmation of HIV 1 or 2 infection AVENIO ctdna panels - Liquid biopsy for circulating tumor DNA, 3 panels: targeted panel (17 genes for cancer therapy selection), expanded panel (77 genes for cancer therapy selection), surveillance panel (197 genes) cobas Liat C.diff Qualitative IVD test, that utilizes real-time PCR, for the direct detection of the tcdb gene of toxigenic C. difficile in unformed stool specimens cobas Liat MRSA/SA Qualitative IVD test, that utilizes real-time PCR, for the direct detection of MRSA and Staphylococcus aureus DNA from nasal swabs Women s Health AMH Immunoassay for the in vitro quantitative determination of anti-mullerian hormone (AMH) in human serum and plasma for the assessment of the ovarian reserve in women presenting to fertility clinics Companion Diagnostics * = Achieve commercial readiness, dependent on Pharma label and approval PD-L1 (SP142) for Bladder Cancer* complementary diagnostic for Tecentriq PD-L1 (SP142) for NSCLC* complementary diagnostic for Tecentriq US WW EU US EU EU US EU EU/US EU EU US EU EU 43

44 Finance Alan Hippe Chief Financial Officer 44

45 YTD Sept 2017: Highlights Sales Strong underlying Group sales growth, particularly in the US (+8%) and International (+7%) regions +5% growth in both divisions Currency impact Negative impact from Other Europe currencies and JPY offset by Lat-Am currencies and USD All growth rates at Constant Exchange Rates (CER) 45

46 Group sales YTD Sept 2017 Sales increase driven by US and Diagnostics Division +10% -2% +4% +2% +5% +5% +5% Pharma Division +5% , ,970 +1,929 United States Europe Intl. Japan Diagnostics Division Group Fx Group CHF 1 Absolute values and growth rates at Constant Exchange Rates (CER) 1 average Full Year 2016 to average YTD Sept 2017 Fx 46

47 Exchange rate impact on sales growth Negative impact from Other Europe currencies and JPY offset by Lat-Am currencies and USD +0.2p +0.2p +0.1p 0.0p -0.1p -0.2p -0.3p CER sales growth YTD Sep 2017 vs. YTD Sep % +5.1% CHF sales growth YTD Sep 2017 vs. YTD Sep 2016 CER Lat-Am USD Other EUR As-Pac JPY Other Europe CHF CER=Constant Exchange Rates 47

48 Low currency impact expected in 2017 CHF / USD Assumed average YTD Average YTD % 1% 0% 0% % Monthly avg fx rates 2017 Fx rates at 30 Sep 2017 J F M A M J J A S O N D 0.99 Assuming the 30 September 2017 exchange rates remain stable until end of 2017, 2017 impact is expected to be (%p): Q1 HY Sep YTD FY CHF / EUR -2% -2% 0% +1% Sales Core operating profit 0 Core EPS J F M A M J J A S O N D 48

49 2017 outlook raised at HY Group sales growth 1 Mid-single digit Core EPS growth 1 Broadly in line with sales growth Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 49

50 Pipeline summary 50

51 Changes to the development pipeline Q update New to phase I New to phase II New to phase III New to registration 3 NMEs: RG6160 NME multiple myeloma RG6147 NME geographic atrophy RG7945 NME - glaucoma 1 NME transitioned from Ph I: RG6100 Tau MAb - Alzheimer s disease 1 AI: RG7388 idasanutlin - polycythemia vera 1 NME transitioned from Ph II: RG6206 anti-myostatin adnectin DMD 1 AI: RG7446 Tecentriq + paclitaxel 1L TNBC 1 AI following filing in US/EU: RG1273 Perjeta + Herceptin HER2+ BC adj 1 AI following filing in US: RG7204 Zelboraf Erdheim- Chester disease Removed from phase I Removed from phase II Removed from phase III Removed from registration 1 AI: RG3616 Erivedge + ruxolitinib myelofibrosis 3 NMEs: RG3637 lebrikizumab atopic dermatitis (out-licensed) RG7745 Flu A MAb influenza A RG7221 vanucizumab - mcrc 2 AIs: RG1273 Perjeta + Herceptin - 1L HER2+ gastric cancer RG7204 Zelboraf BRAFm melanoma adj 1 NME following EU approval: RG7446 Tecentriq 2L muc 2 AIs following EU approval: RG1569 Actemra giant cell arteritis RG7446 Tecentriq 2L+ NSCLC 1 CHU following Japan approval: CHU Actemra Takayasu arteritis and giant cell arteritis 51 Status as of October 19, 2017

52 Roche Group development pipeline RG6026 CD20 TCB heme tumors RG6047 SERD (2) ER+ (HER2-neg) mbc RG6058 TIGIT ± Tecentriq solid tumors RG6114 mpi3k alpha inh HR+ BC RG6146 BET inh combos solid + heme tumors RG multiple myeloma RG6180 personalized cancer vaccine ± T oncology RG6185 pan-raf inh + Cotellic solid tumors RG7155 emactuzumab + Tecentriq solid tumors emactuzumab + selicrelumab solid tumors RG7159 anti-cd20 combos heme tumors RG7386 FAP-DR5 bimab solid tumors RG7421 RG7446 Cotellic + Zelboraf + T Cotellic + T Tecentriq Tecentriq T-based Morpheus platform T + Avastin + Cotellic T ± Avastin ± chemo T ± Avastin ± chemo T + Cotellic T + ipi/ifn T + Tarceva/Alecensa T + anti-cd20 combos T ± lenalidomide ± daratumumab T + K/HP T + HMA T + radium 223 T + guadecitabine T + rucaparib melanoma 2L BRAF WT mm solid tumors NMIBC solid tumors 2/3L CRC HCC, GC, PaC solid tumors solid tumors solid tumors NSCLC heme tumors MM HER2+ BC MDS mcrpc AML ovarian ca RG7461 FAP IL2v FP combos solid tumors RG7601 Venclexta + Cotellic/idasanutlin Venclexta ± azacitadine AML r/r MDS RG7741 ChK1 inh solid tumors RG7802 CEA TCB ± Tecentriq solid tumors Phase I (40 NMEs + 23 AIs) RG7813 CEA IL2v FP* + Tecentriq solid tumors RG7828 CD20 TDB ± Tecentriq heme tumors RG7876 selicrelumab (CD40) + T selicrelumab + vanucizumab solid tumors solid tumors RG7882 MUC16 ADC ovarian ca RG7986 ADC r/r NHL CHU Raf/MEK dual inh solid tumors CHU glypican-3/cd3 bimab solid tumors RG6069 anti-fibrotic agent fibrosis RG6107 C5 inh MAb PNH RG autoimmune diseases RG7880 IL-22Fc inflammatory diseases RG asthma RG6004 HBV LNA HBV RG6080 nacubactam bact.infections RG7854 TLR7 agonist (3) HBV RG7861 anti-s. aureus TAC infectious diseases RG7907 HBV Capsid (2) HBV RG7992 FGFR1/KLB MAb metabolic diseases RG ALS RG6029 Nav1.7 inh (2) pain RG7203 PDE10A inh schizophrenia RG psychiatric disorders IONIS ASO Huntington s RG geographic atrophy RG glaucoma CHU PTH1 recep. ago hypoparathyroidism CHU - hyperphosphatemia New Molecular Entity (NME) RG-No Roche/Genentech Additional Indication (AI) CHU Chugai managed Oncology IONIS IONIS managed Immunology PRO Proximagen managed Infectious Diseases NOV Novimmune managed CardioMetabolism *INN: cergutuzumab amunaleukin Neuroscience **out-licensed to Galderma and Maruho Ophthalmology for atopic dermatitis Other FPI expected Q T=Tecentriq; TCB=T cell bispecific; TDB=T cell dependent bispecific Phase II (19 NMEs + 11 AIs) RG3502 Kadcyla + Tecentriq 2L HER2+ mbc RG7388 Idasanutlin polycythemia vera RG7421 Cotellic + Tecentriq ± taxane TNBC RG7440 ipatasertib 1L TNBC ipatasertib TNBC neoadj RG7596 polatuzumab vedotin DLBCL Venclexta + Rituxan DLBCL RG7601 Venclexta + Rituxan r/r FL Venclexta + azacitadine 1L MDS RG7604 taselisib + letrozole (HER2-neg) BC neoadj RG7686 codrituzumab liver cancer RG3637 lebrikizumab ± Esbriet (NME) IPF RG6125 Cadherin-11 MAb RA RG6149 ST2 MAb asthma RG7159 obinutuzumab lupus RG7625 Cat-S antag autoimmune diseases RG7845 BTK inh RA, lupus, CSU CHU nemolizumab** pruritus in dialysis patients PRO VAP-1 inh inflammatory disease NOV TLR4 MAb autoimmune diseases RG6152 CAP endonuclease inh influenza CHU URAT1 inh gout RG1662 basmisanil CIAS, post-stroke recovery RG6083 olesoxime SMA RG6100 Tau MAb Alzheimer s RG7314 V1a receptor antag autism RG7916 SMN2 splicer(2) SMA RG7935 α-synuclein MAb Parkinson's RG3645 ranibizumab PDS wamd RG7716 VEGF-ANG2 bimab wamd, DME 52 Status as of October 19, 2017

53 Roche Group development pipeline Phase III (9 NMEs + 30 AIs) Registration (2 NMEs + 5 AIs) RG3502 Kadcyla HER2+ BC adj Kadcyla + Perjeta HER2+ BC adj RG6013 emicizumab hemophilia A w/o FVIII inh emicizumab Q4W hemophilia A RG7388 idasanutlin + chemo AML RG7440 ipatasertib + chemo 1L CRPC RG7421 Cotellic + Zelboraf + T BRAFm melanoma Tecentriq NSCLC adj Tecentriq MIBC adj Tecentriq Dx+ 1L sq + non-sq SCLC Tecentriq RCC adj T + nab-paclitaxel 1L non-sq NSCLC T + chemo+ Avastin 1L ovarian cancer T + chemo + Avastin 1L non-sq NSCLC T + chemo + pemetrexed 1L non-sq NSCLC RG7446 T + nab-paclitaxel 1L sq NSCLC T + paclitaxel 1L TNBC T + nab-paclitaxel 1 LTNBC T + nab-paclitaxel TNBC neoadj T + Avastin RCC T + Cotellic 3L CRC T ± chemo 1L muc T + chemo 1L extensive stage SCLC T + enzalutamide CRPC RG7601 RG7604 Venclexta + Rituxan Venclexta + Gazyva Venclexta + bortezomib Venclexta + HMA r/r CLL 1L CLL MM 1L AML taselisib + fulvestrant ER+(HER2-neg) mbc RG105 MabThera pemphigus vulgaris RG1569 Actemra systemic sclerosis RG7413 etrolizumab etrolizumab ulcerative colitis Crohn s RG1450 gantenerumab Alzheimer s RG6168 satralizumab (IL-6R MAb) NMO RG6206 anti-myostatin adnectin DMD RG7412 crenezumab Alzheimer s RG7417 lampalizumab geographic atrophy RG3645 Lucentis 0,3mg PFS 1 DME/DR New Molecular Entity (NME) RG-No Roche/Genentech Additional Indication (AI) CHU Chugai managed Oncology RG1569 Branded as RoActemra (EU) Immunology RG7159 Branded as Gazyvaro (EU) Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other T=Tecentriq RG435 Avastin 1 GBM RG1273 Perjeta + Herceptin HER2+ BC adj RG6013 emicizumab hemophilia A FVIII inh RG7159 Gazyva 2 1L FL RG7204 Zelboraf 1 Erdheim-Chester disease RG7853 Alecensa 1L ALK+ NSCLC RG1594 Ocrevus 3 PPMS + RMS 1 US only 2 Approved in EU 3 Approved in US 53 Status as of October 19, 2017

54 NME submissions and their additional indications Projects currently in phase II and III RG1450 gantenerumab Alzheimer s RG7716 VEGF/ANG2 bimab wamd/dme RG1662 RG6083 basmisanil CIAS, post-stroke recovery olesoxime SMA RG6152 RG3637 CAP endonuclease inh influenza lebrikizumab ± Esbriet IPF RG7388 idasanutlin polycythemia vera RG6100 Tau MAb Alzheimer s RG6125 Cadherin-11 MAb RA RG7440 ipatasertib 1L CRPC RG6206 anti-myostatin adnectin DMD RG6149 ST2 MAb Asthma RG7440 ipatasertib 1L TNBC RG7314 V1 receptor antag autism RG7413 etrolizumab ulcerative colitis RG6013 emicizumab hemophilia A FVIII inh pediatrics and adults RG7604 RG6013 RG6013 taselisib+fulvestrant PIK3CAmut ER+ (HER2-neg) mbc emicizumab hemophilia A FVIII non-inh emicizumab hemophilia A, Q4W RG6168 RG7388 satralizumab IL-6R MAb, SA237 neuromyelitis optica idasanutlin AML RG7440 RG7596 RG7604 ipatasertib TNBC neoadj polatuzumab vedotin DLBCL taselisib + letrozole ER+ (HER2-neg) BC neoadj RG7412 RG7916 RG7935 crenezumab Alzheimer s SMN2 splicer(2) SMA α-synuclein MAb Parkinson s RG7413 etrolizumab Crohn s Cat S antag RG7625 autoimmune diseases BTK inh RG7845 autoimmune diseases and beyond New Molecular Entity (NME) CardioMetabolism Indicates a submission which has occurred with regulatory action pending Unless stated otherwise submissions are planned to occur in US and EU Additional Indication (AI) Oncology Immunology Neuroscience Ophthalmology Other Infectious Diseases 54 Status as of October 19, 2017

55 AI submissions for existing products Projects currently in phase II and III RG105 MabThera pemphigus vulgaris RG1569 Actemra systemic sclerosis RG3502 Kadcyla + Tecentriq 2L Her2+ mbc RG3645 ranibizumab PDS wamd RG3645 RG435 RG1273 RG7159 RG7204 Lucentis 0.3mg PFS (US) DME/DR Avastin (US) GBM Perjeta + Herceptin HER2+ BC adj. Gazyva (US) 1L FL Zelboraf (US) Erdheim-Chester disease RG7446 RG7446 RG7446 RG7446 RG7446 Tecentriq + chemo + Avastin 1L non-sq NSCLC Tecentriq + nabpaclitaxel 1L sq NSCLC Tecentriq + nabpaclitaxel 1L non-sq NSCLC Tecentriq + chemo + pemetrexed 1L non-sq NSCLC Tecentriq + chemo 1L extens. stage SCLC RG7446 RG7421 RG7446 RG7446 RG7446 Tecentriq + Cotellic 3L CRC Cotellic + Tecentriq + Zelboraf BRAFmut melanoma Tecentriq 1L non-sq + sq NSCLC (Dx+) Tecentriq+ nabpaclitaxel TNBC neoadj Tecentriq + paclitaxel 1L TNBC RG3502 RG3502 RG7601 RG7601 RG7601 Kadcyla + Perjeta HER2+ BC adj. Kadcyla HER2+ BC adj. Venclexta + Rituxan r/r FL Venclexta + Rituxan DLBCL Venclexta + HMA 1L AML RG7159 RG7446 RG7446 RG7446 RG7446 obinutuzumab lupus nephritis Tecentriq ± chemo 1L muc Tecentriq NSCLC adj Tecentriq MIBC adj Tecentriq + enzalutamide CRPC RG7601 Venclexta + Rituxan r/r CLL RG7446 Tecentriq + Avastin RCC RG7601 Venclexta + Gazyva 1L CLL RG7601 Venclexta + HMA 1L MDS RG7446 Tecentriq RCC adj RG7853 Alecensa 1L ALK+ NSCLC RG7446 Tecentriq + nabpaclitaxel TNBC RG7601 Venclexta + bortezomib MM RG7421 Cotellic + Tecentriq ± taxane TNBC RG7446 Tecentriq + chemo + Avastin 1L ovarian cancer and beyond New Molecular Entity (NME) CardioMetabolism Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU Additional Indication (AI) Oncology Immunology Neuroscience Ophthalmology Other Infectious Diseases 55 Status as of October 19, 2017

56 Major granted and pending approvals 2017 US EU Japan-Chugai Approved RG105 RG7446 RG1569 RG1569 RG1594 RG3645 RG3645 Rituxan Hycela (SC) NHL/CLL June 2017 Tecentriq 1L bladder cancer, cis-ineligible April 2017 Actemra giant cell arteritis May 2017 Actemra CRS August 2017 Ocrevus PPMS & RMS March 2017 Lucentis mcnv January 2017 Lucentis diabetic retinopathy w/o DME April 2017 RG435 RG7159 RG7446 RG7446 RG7853 RG1569 Avastin chemo backbone extension rel. OC Pt-sensitive June 2017 Gazyva 1L follicular lymphoma September 2017 Tecentriq muc 2L September 2017 Tecentriq 2L+ NSCLC September 2017 Alecensa 2L ALK+ NSCLC February 2017 Actemra giant cell arteritis September 2017 CHU Actemra Takayasu arteritis and giant cell arteritis August 2017 Pending Approval RG435 RG1273 RG6013 RG7159 RG7204 RG7853 Avastin GBM Filed February 2017 Perjeta + Herceptin HER2+ BC adj Filed July 2017 emicizumab hemophilia A FVIII inh (pediatrics and adults) Filed June 2017 Gazyva follicular lymphoma 1L Filed June 2017 Zelboraf Erdheim-Chester disease Filed June 2017 Alecensa 1L ALK+ NSCLC Filed May 2017 RG1273 RG6013 RG7853 RG1594 Perjeta + Herceptin HER2+ BC adj Filed August 2017 emicizumab hemophilia A FVIII inh (pediatrics and adults) Filed June 2017 Alecensa 1L ALK+ NSCLC Filed March 2017 Ocrevus PPMS & RMS Filed April 2016 RG6013 RG7446 New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology Infectious Diseases emicizumab hemophilia A FVIII inh (pediatrics and adults) Filed July 2017 Tecentriq 2L+ NSCLC Filed February 2017 CardioMetabolism Neuroscience Ophthalmology Other 56 Status as of October 19, 2017

57 Roche Group development pipeline Combinations RG6058 TIGIT ± Tecentriq solid tumors RG6146 BET inh combos solid + heme tumors RG6180 personalized cancer vaccine ± T oncology RG6185 pan-raf inh + Cotellic solid tumors RG7155 emactuzumab + Tecentriq solid tumors emactuzumab + selicrelumab solid tumors RG7159 anti-cd20 combos heme tumors RG7421 RG7446 Cotellic + Zelboraf + T Cotellic + T T-based Morpheus platform T + Avastin + Cotellic T ± Avastin ± chemo T ± Avastin ± chemo T + Cotellic T + ipi/ifn T + Tarceva/Alecensa T + anti-cd20 combos T ± lenalidomide ± daratumumab T + K/HP T + HMA T + radium 223 T + guadecitabine T + rucaparib melanoma BRAF WT mm2l solid tumors 2/3L CRC HCC, GC, PaC solid tumors solid tumors solid tumors NSCLC heme tumors MM HER2+ BC MDS mcrpc AML ovarian ca RG7461 FAP IL2v FP combos solid tumors RG7601 Venclexta + Cotellic/idasanutlin Venclexta ± azacitidine Phase I (10 NMEs + 21 AIs) AML r/r MDS RG7828 CEA TCB ± Tecentriq solid tumors RG7813 CEA IL2v FP* + Tecentriq solid tumors RG7828 CD20 TDB ± Tecentriq heme tumors RG7876 RG3502 Kadcyla + Tecentriq 2L HER2+ mbc RG7421 Cotellic + Tecentriq ± taxane TNBC RG7601 Phase II (1 NME + 6 AIs) Venclexta + Rituxan Venclexta + Rituxan Venclexta + azacitidine DLBCL r/r FL 1L MDS RG7604 taselisib + letrozole (HER2-) BC neoadj RG3637 lebrikizumab ± Esbriet (NME) IPF New Molecular Entity (NME) RG-No Roche/Genentech Additional Indication (AI) CHU Chugai managed Oncology Immunology selicrelumab (CD40) + T selicrelumab + vanucizumab solid tumors solid tumors *INN: cergutuzumab amunaleukin T=Tecentriq; TCB=T cell bispecific TDB=T cell dependent bispecific Phase III (3 NMEs + 19 AIs) RG3502 Kadcyla + Perjeta HER2+ BC adj RG7388 idasanutlin + chemo AML RG7440 ipatasertib + chemo 1L CRPC RG7421 Cotellic + Zelboraf + T BRAFm melanoma T + nab-paclitaxel 1L non-sq NSCLC T + chemo + Avastin 1L ovarian cancer T + chemo + Avastin 1L non-sq NSCLC T + chemo + pemetrexed 1L non-sq NSCLC T + nab-paclitaxel 1L sq NSCLC T + nab-paclitaxel 1L TNBC RG7446 T + nab-paclitaxel TNBC neoadj T + Cotellic 3L CRC T + Avastin RCC T ± chemo 1L muc T + chemo 1L extens. stage SCLC T + enzalutamide CRPC T + paclitaxel 1L TNBC Venclexta + Rituxan r/r CLL RG7601 Venclexta + Gazyva 1L CLL Venclexta + bortezomib MM Venclexta + HMA 1L AML RG7604 taselisib + fulvestrant ER+ (HER2-neg) mbc Registration (1 AI) RG1273 Perjeta + Herceptin HER2+ BC adj 57 Status as of October 19, 2017

58 Cancer immunotherapy pipeline overview RG6026 CD20 TCB hematopoietic tumors RG6058 TIGIT ± Tecentriq solid tumors RG multiple myeloma RG6180 personalized cancer vaccine ± T oncology RG7155 RG7421 RG7446 emactuzumab + Tecentriq solid tumors emactuzumab + selicrezumab solid tumors Cotellic + Zelboraf + T Cotellic + T Tecentriq Tecentriq melanoma BRAF WT mm2l solid tumors NMIBC T-based Morpheus platform pancreatic ca T + Cotellic ± Avastin T ± Avastin ± chemo T ± Avastin ± chemo T + Cotellic T + ipi/ifn T + Tarceva/Alecensa 2/3L CRC HCC, GC, PaC solid tumors solid tumors solid tumors NSCLC T + anti-cd20 multiple combos lymphoma T ± lenalidomide ± daratumumab T + K/HP T + HMA T + radium 223 T + guadecitabine T + rucaparib MM HER2+ BC MDS mcrpc AML ovarian ca RG7461 FAP IL2v FP + Tecentriq ± Avastin RCC RG7802 CEA TCB ± Tecentriq solid tumors RG7813 CEA IL2v FP* + Tecentriq solid tumors RG7828 CD20 TDB ± Tecentriq solid tumors RG7876 selicrelumab (CD40) + T selicrelumab + vanucizumab Phase I (10 NMEs + 30 AIs) solid tumors solid tumors AMGN** RG7446 ** External collaborations: HALO Halozyme PEGPH20; INCY- Incyte IDO inh; CLDX - Celldex CD27 MAb; CRVS Corvus ADORA2A antag; KITE Kite KTE-C19; AMGN Amgen oncolytic virus; JNJ Janssen CD38 MAb; CLVS Clovis PARP inh; EPZM Epizyme EZH2 inh; BLRX - BioLine Rx CXCR4 antag; IMDZ Immune Design CMB305; SNDX Syndax HDAC inh New Molecular Entity (NME) RG-No Roche/Genentech Additional Indication (AI) Oncology Tecentriq + talimogene laherp TNBC, CRC BLRX** Tecentriq + BL-8040 AML, solid tumors CLDX** Tecentriq + varlilumab solid tumors CLVS** Tecentriq + rucaparib ovarian ca CRVS** Tecentriq + CPI-444 solid tumors EPZM** Tecentriq + tazemetostat r/r DLBCL HALO** Tecentriq + PEGPH20 CCC, GBC INCY** Tecentriq + epacadostat solid tumors JNJ** Tecentriq ± daratumumab solid tumors KITE** Tecentriq + KTE-C19 r/r DLBCL MORPHEUS Platform - Phase Ib/II (2 AIs) T-based Morpheus T-based Morpheus pancreatic cancer gastric cancer *INN: cergutuzumab amunaleukin T=Tecentriq; TCB=T cell bispecific TDB=T cell dependent bispecific Phase II (4 AIs) RG3502 Kadcyla + Tecentriq 2L HER2+ mbc RG7421 Cotellic + Tecentriq ± taxane TNBC IMDZ** Tecentriq + NY-ESO-1 soft tissue sarcoma SNDX** Tecentriq + entinostat TNBC Phase III (18 AIs) RG7421 Cotellic + Zelboraf + T BRAFm melanoma Tecentriq NSCLC adj Tecentriq MIBC adj Tecentriq Dx+ 1L sq + non-sq SCLC Tecentriq RCC adj T + nab-paclitaxel 1L non-sq NSCLC T + chemo + Avastin 1L ovarian cancer T + chemo + Avastin 1L non-sq NSCLC T + chemo + pemetrexed 1L non-sq NSCLC RG7446 T + nab-paclitaxel 1L sq NSCLC T + nab-paclitaxel 1L TNBC T + nab-paclitaxel TNBC neoadj T + Avastin RCC T + Cotellic 3L CRC T ± chemo 1L muc T + chemo 1L extensive stage SCLC T + enzalutamide CRPC T + paclitaxel 1L TNBC 58 Status as of October 19, 2017

59 Doing now what patients need next